Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Up 27.2% in March

Iterum Therapeutics plc (NASDAQ:ITRMGet Rating) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 3,550,000 shares, an increase of 27.2% from the March 15th total of 2,790,000 shares. Based on an average trading volume of 1,480,200 shares, the short-interest ratio is presently 2.4 days.

ITRM traded down $0.01 on Monday, reaching $0.30. The stock had a trading volume of 9,761 shares, compared to its average volume of 1,488,973. Iterum Therapeutics has a 12-month low of $0.28 and a 12-month high of $2.52. The company has a quick ratio of 6.43, a current ratio of 6.43 and a debt-to-equity ratio of 0.14. The business’s 50-day moving average price is $0.37 and its two-hundred day moving average price is $0.44.

Iterum Therapeutics (NASDAQ:ITRMGet Rating) last released its quarterly earnings results on Monday, March 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. During the same quarter in the previous year, the company earned ($0.11) earnings per share. On average, research analysts expect that Iterum Therapeutics will post -0.24 earnings per share for the current year.

Large investors have recently modified their holdings of the stock. Squarepoint Ops LLC raised its position in Iterum Therapeutics by 106.9% during the 3rd quarter. Squarepoint Ops LLC now owns 52,503 shares of the company’s stock worth $29,000 after buying an additional 27,121 shares during the last quarter. Geode Capital Management LLC raised its position in Iterum Therapeutics by 27.9% during the 3rd quarter. Geode Capital Management LLC now owns 129,271 shares of the company’s stock worth $72,000 after buying an additional 28,169 shares during the last quarter. Morgan Stanley raised its position in Iterum Therapeutics by 359.6% during the 1st quarter. Morgan Stanley now owns 74,495 shares of the company’s stock worth $105,000 after buying an additional 58,285 shares during the last quarter. Virtu Financial LLC purchased a new position in Iterum Therapeutics during the 4th quarter worth $164,000. Finally, Franklin Resources Inc. purchased a new position in Iterum Therapeutics during the 3rd quarter worth $215,000. Hedge funds and other institutional investors own 3.32% of the company’s stock.

Separately, Zacks Investment Research downgraded shares of Iterum Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 5th.

About Iterum Therapeutics (Get Rating)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Featured Stories

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.